News >

Frontline Atezolizumab Regimen Approved in Europe for NSCLC

Gina Columbus @ginacolumbusonc
Published: Friday, Mar 08, 2019

Dr. Sandra Horning

Sandra Horning, MD
The European Commission has approved and granted marketing authorization to the frontline combination of atezolizumab (Tecentriq), bevacizumab (Avastin), paclitaxel, and carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer (NSCLC).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x